This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
A secondary strainer stretched with sheer fabric is another option for passive protection, which fits inside the original strainer. Materials such as Tetex® (Stabiltex®), permits viewing of the back. The secondary strainer must be flush and fixed with the textile and must not move inside the original strainer. Secondary strainers require awareness of the properties of the textiles and original mounting materials. Challenges: “Textile conservators are often required to treat complex feathered objects found in textile collections. Traditional cleaning methods are not always suitable for every situation and alternative methods may therefore be necessary, particularly for localized soil removal.”
Today the Catholic devotions to the Holy Face of Jesus are usually associated with the negative image of the Shroud of Turin, as first captured in Secondo Pia's 1898 photograph. However, these devotions predate Pia's image, having been established in 1844 by the Carmelite nun Marie of St Peter, based on depictions of Jesus before his crucifixion and associated with the tradition of the Veil of Veronica. This devotion was then promoted by a French Catholic layman, Leo Dupont, who became known as the "Apostle of the Holy Face". In 1851 Dupont formed the "Archconfraternity of the Holy Face" in the city of Tours. Pope Leo XIII approved the devotion to the Holy Face in 1885. The popular French Saint Thérèse of Lisieux took the name "Thérèse of the Child Jesus and the Holy Face" when she became a Discalced Carmelite in 1889. Saint Thérèse, who died in 1897, also helped to spread the devotion to the Holy Face before it became associated with Pia's photographic image of the Shroud of Turin. The modern devotion to the Holy Face centered on the negative photographic image from the Shroud of Turin derives principally from an Italian nun born in Milan, Maria Pierina De Micheli, who reported having visions of Jesus starting in 1936. Sister Maria Pierina designed a "Holy Face Medal", based on Secondo Pia's photographs. This medal was eventually approved for private devotion by Pope Pius XII.
== Further reading == Louis Beres, Apocalypse: Nuclear Catastrophe in World Politics. The risks and consequences of nuclear war and nuclear terrorism. University of Chicago Press, Chicago, 1980. ISBN 9780226043609 Laura Grego and David Wright, "Broken Shield: Missiles designed to destroy incoming nuclear warheads fail frequently in tests and could increase global risk of mass destruction", Scientific American, vol. 320, no. no. 6 (June 2019), pp. 62–67. "Nuclear-armed missiles are a political problem that technology cannot solve.... Current U.S. missile defense plans are being driven largely by technology, politics and fear. Missile defenses will not allow us to escape our vulnerability to nuclear weapons. Instead large-scale developments will create barriers to taking real steps toward reducing nuclear risks—by blocking further cuts in nuclear arsenals and potentially spurring new deployments." (p. 67.) Jessica T. Mathews, "The New Nuclear Threat", The New York Review of Books, vol. LXVII, no. 13 (20 August 2020), pp. 19–21. "[P]owerful reasons to doubt that there could be a limited nuclear war [include] those that emerge from any study of history, a knowledge of how humans act under pressure, or experience of government." (p. 20.) National Academies of Sciences, Engineering, and Medicine. 2025. Potential Environmental Effects of Nuclear War. The National Academies Press. "Possibility of Nuclear War in Asia: An Indian Perspective", a project of United Service Institution of India, USI, Discusses the possibility of a nuclear war in Asia from the Indian point of view.
The enthesis (plural entheses) is the connective tissue which attaches tendons or ligaments to a bone. There are two types of entheses: fibrous entheses and fibrocartilaginous entheses. In a fibrous enthesis, the collagenous tendon or ligament directly attaches to the bone. In a fibrocartilaginous enthesis, the interface presents a gradient that crosses four transition zones:
Sources: en.wikipedia.org
Emerging methods for single-cell mass-spectrometry analysis promise to enable studying signal transduction with single-cell resolution. In notch signaling, direct contact between cells allows for precise control of cell differentiation during embryonic development. In the worm Caenorhabditis elegans, two cells of the developing gonad each have an equal chance of terminally differentiating or becoming a uterine precursor cell that continues to divide. The choice of which cell continues to divide is controlled by competition of cell surface signals. One cell will happen to produce more of a cell surface protein that activates the Notch receptor on the adjacent cell. This activates a feedback loop or system that reduces Notch expression in the cell that will differentiate and that increases Notch on the surface of the cell that continues as a stem cell.
==== Bevacizumab ==== Through binding to VEGFR and other VEGF receptors in endothelial cells, VEGF can trigger multiple cellular responses like promoting cell survival, preventing apoptosis, and remodeling cytoskeleton, all of which promote angiogenesis. Bevacizumab (brand name Avastin) traps VEGF in the blood, lowering the binding of VEGF to its receptors. This results in reduced activation of the angiogenesis pathway, thus inhibiting new blood vessel formation in tumors. After a series of clinical trials in 2004, Avastin was approved by the FDA, becoming the first commercially available anti-angiogenesis drug. FDA approval of Avastin for breast cancer treatment was later revoked on November 18, 2011.
== Further reading == Mortison, JD; Sherman, DH (2010). "Frontiers and opportunities in chemoenzymatic synthesis". J Org Chem. 75 (21): 7041–51. doi:10.1021/jo101124n. PMC 2966535. PMID 20882949. Kim, Jinhyun; Lee, Sahng Ha; Tieves, Florian; Paul, Caroline E.; Hollmann, Frank; Park, Chan Beum (5 July 2019). "Nicotinamide adenine dinucleotide as a photocatalyst". Science Advances. 5 (7): eaax0501. doi:10.1126/sciadv.aax0501.
=== Environmental contaminants === Since American kestrels are carnivores, toxic chemical runoff ingested by their prey can concentrate at high levels in their blood. Wild kestrels are subject to immunomodulation, or an altered immune response, to polybrominated diphenyl ethers (PBDEs), a group of industrial flame retardants that may leach from factories into the environment. When PBDEs accumulate in body tissues of kestrels, the T-cell mediated immune response decreases in efficiency. As a result, kestrels that ingest PBDEs may not respond sufficiently to viruses or other invading microorganisms. In addition, certain PBDEs may suppress the growth and development of the spleen and bursa in American kestrels. While PBDEs can affect immune response and suppress growth of certain organs, they can also affect the thyroid system of American Kestrels. Exposure to PBDEs in vivo can alter the thyroid system and retinol concentrations in kestrels. This leads to oxidative stress, lipid peroxidation, and changes in glutathione metabolism. These systems are important in early development, growth, regulation of metabolism, thermoregulation, and reproduction. Oxidative stress is also known to contribute to cancers and neurological diseases. Exposure to polychlorinated biphenyls (PCBs) might also affect American Kestrel reproduction. It was found that PCBs affect the function of carotenoids in kestrels. This led to changes in coloration, especially during breeding season for adults. PCB-exposed males where duller and contributed less to egg incubation than unexposed males.
On Valve's official website circa 2010, his function was described as follows: "Kelly is Valve's senior audio producer, responsible for creating sound effects & music." Around March 2011, Kelly Bailey left Valve with colleague Mike Dussault to work on their project Sunspark Labs LLC, launched in December 2010, developing iOS applications, their first being "Morfo", released in June 2011. The news caused some concern and displeasure from the Steam community due to the lack of any public farewell or notification regarding Bailey's departure. However, at a press conference in February 2014, Mike Morasky (the current composer at Valve), stated that Kelly Bailey was working with Valve again. On 24 September 2015, a collection of new music composed by Bailey was released as a custom music kit in Counter-Strike: Global Offensive titled Hazardous Environments. The music kit's description states that it was "inspired by the darker side of the Half-Life universe". On 18 March 2016, Forbes wrote that Bailey is no longer with Valve but that he has created his own video game company, IndiMo Labs, and that he had been spending sixteen hours a day for the previous seven months as the sole developer behind Vanishing Realms: Rite of Steel, a virtual reality video game with RPG elements for the HTC Vive. The game released as an early access title on Steam on 5 April 2016, the same day the HTC Vive was launched.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。